PRIMORDIAL GENETICS, INC.
San Diego, CA · Founded 2013 · CIK 0001593413 · Biotech · Acquired
Enzymatic DNA and RNA synthesis platform using template-independent DNA polymerases for manufacturing oligonucleotides
- Grants
- $4.5M
- 5 awards
- Sector median: 1
- Raised
- $1.6M
- 4 Form D · Oct 2015
- 132 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 9
- 2 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20132015201720192021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $180,000 | |
| Private capital raised | Form D · SEC | $414,800 | |
| Private capital raised | Form D · SEC | $625,219 | |
| Private capital raised | Form D · SEC | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Discovery and development of single-subunit RNA polymerases for efficient RNA manufacturing | $224,963 | |
| Federal grant | Department of Energy · Phase I · Discovery and optimization of effective plastic depolymerizing enzymes | $199,999 | |
| Federal grant | Department of Health and Human Services · Phase I · DNA 3.0: Developing novel enzymes for DNA synthesis with deep learning and combinatorial genetics | $426,524 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of superior polymerases for next-generation mRNA therapeutic and vaccine manufacturing | $1,621,333 | |
| Federal grant | Department of Health and Human Services · Phase II · DNA 3.0: Development of a novel, efficient and cost-effective enzymatic process for synthesis of DNA oligonucleotides | $2,043,743 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3348 | Attovia Therapeutics | — | — |
| 3349 | CETYA THERAPEUTICS, INC. | — | — |
| 3350 | Aethl Bio, Inc. | — | $1.6M |
| 3351 | PRIMORDIAL GENETICS, INC. | — | $1.6M |
| 3352 | RADIA TECHNICAL IMAGING LLC | — | $37K |
| 3353 | INFINITE ENERGY LLC | — | — |
| 3354 | VANGUARD THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Dominick MendolaDirector
- Helge ZielerDirector · Executive Officer
Patents
- Compositions For Improving Cells And Organismsgranted
- Methods And Compositions For Creating Altered And Improved Cells And Organismsapplication
- Methods And Compositions For Creating Altered And Improved Cells And Organismsgranted
- Compositions And Methods For Enzymatic Nucleic Acid Synthesisapplication
- Methods And Compositions For Protein Engineeringapplication
- Methods And Compositions For Manufacturing Polynucleotidesapplication
- Methods And Compositions For Manufacturing Polynucleotidesapplication
- Methods And Compositions For Nucleic Acid Synthesisapplication
- Methods And Compositions For Nucleic Acid Synthesisapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.